KK B.M.L

4694

Equity

ISIN JP3799700004 / Valor 789977

Tokyo Stock Exchange (2024-09-13)

JPY 2,642.00-0.68%

KK B.M.L
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

KK B.M.L is a Japanese company specializing in clinical laboratory testing and diagnostic services.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales Decline

KK B.M.L's consolidated net sales for the fiscal year 2023, which ended on March 31, 2024, were ¥137,964 million. This represents a 13.5% decrease compared to the previous fiscal year. The decline in net sales was primarily due to a significant reduction in demand for COVID-19-related testing.

Operating Profit Drop

For the same period, KK B.M.L reported an operating profit of ¥9,167 million, marking a substantial 61.7% decrease year-on-year. The drop in operating profit was influenced by the reduced sales from COVID-19-related testing and increased costs of raw materials and energy.

Ordinary Profit and Net Income

KK B.M.L's ordinary profit for fiscal 2023 was ¥9,605 million, a 60.3% decrease from the previous year. The profit attributable to owners of the parent company also saw a significant decline, falling by 61.3% to ¥6,034 million.

Dividends

KK B.M.L declared a total dividend of ¥80.00 per share for fiscal 2023, down from ¥100.00 per share in the previous year. The dividend payout ratio increased to 51.7%, reflecting the lower earnings for the year.

Financial Position

As of March 31, 2024, KK B.M.L's total assets stood at ¥170,991 million, with net assets amounting to ¥130,140 million. The equity ratio improved slightly to 73.6%, up from 72.5% in the previous fiscal year, indicating a stable financial position despite the challenging operating environment.

Summarized from source with an LLMView Source

Key figures

-7.85%1Y

-41.6%3Y

-10.8%5Y

Performance

22.6%1Y

25.1%3Y

28.9%5Y

Volatility